Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
DMF submissions in 2020: Industry sustains its filing momentum
In case you thought Covid-19 had slowed down the speed at
which generic active
pharmaceutical ingr
